Biotech Startups

Kinomica develops mass spectrometry-based diagnostic tests that measure protein activity to predict patient responses to multiple drugs. The company aims to advance precision medicine by enabling companion diagnostics that help match patients to appropriate therapeutic options.

1 investor

Kinoxis Therapeutics develops novel therapeutics targeting inflammatory signaling pathways in the nervous system to address unmet needs in CNS disorders, with initial focus on treatments for agitation and pain.

1 investor

Kintsugi Therapeutics is a preclinical-stage biopharmaceutical company developing first-in-class endoplasmic reticulum stress inhibitors for treating non-alcoholic steatohepatitis and other liver conditions.

1 investor

1 investor

FODZYME develops an enzyme powder supplement that breaks down FODMAPs in food, particularly fructans found in garlic, onions, and wheat, for people with digestive sensitivities. The product targets individuals who need to manage FODMAP intolerance to improve their diet flexibility and quality of life.

1 investor

1 investor

KLISBio develops a silk fibroin-based biointegrative platform for nerve repair and other medical applications. The company serves medtech markets focused on biocompatible medical devices and biomaterials.

1 investor

Klotho Therapeutics is a biotech company developing protein-based therapeutics that mimic the natural human Klotho protein to address age-related diseases including cognitive decline, kidney disease, diabetes, and cancer. The company focuses on longevity treatment and aims to enter human trials within two years targeting kidney disease.

1 investor

Klyne develops binding affinity models for molecular prediction and offers a low-cost virtual screening service aimed at hit discovery and hit-to-lead optimization projects in drug discovery labs. It targets companies working on early-stage pharmaceutical research with limited budgets.

1 investor

Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients. The company serves oncologists and cancer patients through computational analysis of biomaterials and drug-discovery data.

1 investor

Kobuk Therapeutics is developing a biologics platform aimed at treating autoimmune diseases by resetting the immune system to a healthy state while preserving protective immunity.

1 investor

The company uses cellular agriculture and bio-technology to isolate cells from premium cacao strains, culture them in optimized conditions, upscale biomass in bioreactors, and process cocoa for various applications.

1 investor

KolateAI provides AI-driven software solutions to optimize the drug development process, including clinical trials and real-world studies. The platform serves pharmaceutical companies and research organizations seeking to improve efficiency and accelerate drug development timelines.

1 investor

1 investor

Kompass Diagnostics is developing a rapid point-of-care hormone testing platform that uses a cartridge-based analyzer to quantify hormone levels quickly and store results in EHR systems. Its tests target fertility, reproductive, and thyroid monitoring for clinics, satellite locations, Ob/Gyn providers, and diagnostic centers.

1 investor

Korio provides RTSM (Randomization and Trial Supply Management) software for clinical trials, with a focus on experienced project management and continuity throughout the study lifecycle. The company serves clinical operations teams and sponsors managing treatment assignment and supply logistics in regulated pharmaceutical trials.

1 investor

KORSUVA is a prescription medicine that treats moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis. The product is marketed by Vifor (International) Inc.

1 investor

KOTAI Biotechnologies develops an immune AI platform and big data analysis pipeline that combines artificial intelligence with immunology for antibody and immune-repertoire analysis. The company serves pharmaceutical and life-science research applications such as antibody modeling, single-cell analysis, and cancer and infectious-disease immunology research.

1 investor

Serkanto AI is a platform that uses machine learning and deep learning to identify and validate bioactive RNAs in medicinal plants, fungi, and fresh foods for natural ingredient development. The platform serves food, supplement, and cosmetics companies by predicting bioactive RNA candidates, validating them through laboratory assays, and producing stabilized bioactive ingredients.

1 investor

A bioinformatics company applying genetics and selective breeding methods to livestock, offering genetic analysis for animal husbandry and breeding programs. It serves agricultural and animal-breeding clients.

1 investor

Esencia Foods (now KULT FARM) uses mycelium solid-state fermentation with legumes to make vegan meat, fish, and hybrid meat products such as mince, chunks, and slices with clean labels. It sells to food service and retail businesses and has filed patents on its fermentation platform.

1 investor

Kuros Biosciences is a Swiss biotech company developing biologic technologies for bone healing and bone grafts, primarily for spine, extremities, and pelvis surgical applications. Originally a spin-off of the Swiss Federal Institute of Technology in Zurich, it is publicly listed on the SIX Swiss Stock Exchange and operates in Switzerland, the Netherlands, and the USA.

1 investor

Kvantify develops software that runs on both quantum computers and classical computing architectures (CPU/GPU) to solve chemistry and biology problems for molecular and drug discovery. Its algorithms distribute calculations across quantum and classical compute resources in high-performance computing environments to accelerate the discovery of disease-curing molecules.

1 investor

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.

1 investor